The Latest Cardiac and Vascular News
Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia DUBLIN, Oct. 18, 2020 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first-ever results from the IN.PACT […]
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN, Oct. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced it will begin a randomized, head-to-head study comparing two transcatheter aortic […]
Half Moon Medical’s Technology Now Ready for Evaluation in Early Feasibility Study DUBLIN, Oct. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company incubator – dating back to […]
DUBLIN, Oct. 1, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients […]
Avenu’s Percutaneous Fistula Creation Technology Will Strengthen the Medtronic Peripheral Vascular Access Portfolio and Reinforce Medtronic’s Commitment to Improving Outcomes for Patients with End-Stage Renal Disease DUBLIN, Sept. 30, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced […]
DUBLIN, Sept. 24, 2020 /PRNewswire/ — Medtronic plc (the “Company”) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of €1,250,000,000 principal amount of 0.000% senior notes due 2023, €1,000,000,000 principal amount of […]
DUBLIN, Sept. 23, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first enrollments in the ALLEVIATE-HF clinical trial which will evaluate the ability of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in identifying patients at high-risk […]
DUBLIN, Sept. 22, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the TYRX™ Absorbable Antibacterial Driveline Wrap, which is intended to securely hold a […]
Economic Analysis of the WRAP-IT Patient Population in Circulation: Arrhythmia and Electrophysiology Long-Term Results from WRAP-IT, Data on Impact of Infections Also Published DUBLIN, Sept. 16, 2020 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from […]
Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation DUBLIN, Sept. 9, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. […]
